Organogenesis (NASDAQ:ORGO) Shares Gap Up – What’s Next?

Organogenesis Holdings Inc. (NASDAQ:ORGO) gapped up prior to trading on Tuesday . The stock had previously closed at $5.42, but opened at $5.56. Organogenesis shares last traded at $5.20, with a volume of 239,503 shares trading hands.

Analyst Ratings Changes

Separately, Morgan Stanley lifted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Trading Down 10.0 %

The firm’s 50 day simple moving average is $4.16 and its two-hundred day simple moving average is $3.56. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The stock has a market cap of $596.09 million, a P/E ratio of -78.33 and a beta of 1.66.

Insider Activity at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the sale, the director now owns 166,879 shares of the company’s stock, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 36.90% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its holdings in shares of Organogenesis by 5.2% in the 4th quarter. Wellington Management Group LLP now owns 254,282 shares of the company’s stock worth $814,000 after acquiring an additional 12,634 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Organogenesis by 16.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 39,159 shares of the company’s stock worth $125,000 after purchasing an additional 5,551 shares in the last quarter. Mackenzie Financial Corp raised its position in shares of Organogenesis by 255.1% during the 4th quarter. Mackenzie Financial Corp now owns 76,353 shares of the company’s stock worth $244,000 after buying an additional 54,850 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in shares of Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock worth $39,952,000 after acquiring an additional 645,000 shares during the period. Finally, Virtus Investment Advisers Inc. bought a new position in shares of Organogenesis in the fourth quarter valued at approximately $157,000. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.